Wordt geladen...
Lenalidomide in Diffuse Large B-Cell Lymphomas
Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease. Lenalidomide, an immunomodulatory agent,...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Hindawi Publishing Corporation
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3390034/ https://ncbi.nlm.nih.gov/pubmed/22792112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/498342 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|